Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-023-01340-5
Abstract: The combination of niraparib and abiraterone acetate (AA) plus prednisone is under investigation for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Regular-strength (RS) and lower-strength (LS)… read more here.
Keywords: niraparib abiraterone; sac; dat; study ... See more keywords